Abstract
A double-blinded, placebo-controlled cross-over trial was carried out with 27 hypercholesterolemic men with coronary heart disease. During the 6-week treatment period lovastatin (60 mg/day) decreased fasting serum LDL cholesterol by 45%, LDL phosphorus by 38% and apoB by 33%. Ubiquinol content diminished by 13% as measured per LDL phosphorus. When LDL was oxidized ex vivo with AMVN both LDL ubiquinol and alpha-tocopherol were exhausted faster after lovastatin treatment compared to placebo, by 24% (P < 0.005) and 36% (P < 0.0001), respectively. Lag time in copper-induced oxidation of LDL decreased by 7% (P < 0.01). This suggests diminished antioxidant-dependent resistance of LDL to the early phase of oxidative stress.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Anticholesteremic Agents / therapeutic use*
-
Antioxidants / administration & dosage*
-
Apolipoproteins A / blood
-
Apolipoproteins B / blood
-
Cholesterol / blood
-
Cholesterol, LDL / blood
-
Copper
-
Coronary Disease / complications*
-
Coronary Disease / metabolism
-
Cross-Over Studies
-
Double-Blind Method
-
Humans
-
Hypercholesterolemia / blood
-
Hypercholesterolemia / complications
-
Hypercholesterolemia / drug therapy*
-
Lovastatin / therapeutic use*
-
Male
-
Middle Aged
-
Oxidation-Reduction
-
Triglycerides / blood
-
Ubiquinone / analogs & derivatives*
-
Ubiquinone / blood
-
Ubiquinone / chemistry
-
Vitamin E / blood*
-
Vitamin E / chemistry
Substances
-
Anticholesteremic Agents
-
Antioxidants
-
Apolipoproteins A
-
Apolipoproteins B
-
Cholesterol, LDL
-
Triglycerides
-
Ubiquinone
-
Vitamin E
-
Copper
-
Cholesterol
-
Lovastatin
-
ubiquinol